Oracle Buys Intellectual Property Assets of Conformia.
Redwood Shores, CA : Oracle announced today that it has acquired the intellectual property assets of Conformia Software. Conformia’s Product and Process Lifecycle Management (PPLM) software has unique capabilities for Life Sciences companies to manage drug design, development and transfer to production across Bio, Pharmaceutical and Chemical drug components.
Oracle plans to integrate Conformia’s product and technology into Oracle Agile PLM solution to offer an end-to-end solution for managing drug development, packaging and commercialization.
"The addition of Conformia Software technology underscores Oracle’s commitment to provide customers with a differentiated, out-of-box industry-based solution," said Oracle Vice President of PLM Strategy Hardeep Gulati.
Oracle plans to provide integrations to Oracle applications, Oracle Health Sciences applications and 3rd party systems. This combination will enable Pharmaceutical and Bio-technology companies to accelerate innovation, meet regulatory objectives and improve productivity.
Financial details of the transaction were not disclosed.
"Oracle’s PLM offering will give our Life Sciences industry customers a complete solution to manage drug design, development to commercialization," he added.
Popular Articles
- Femap® From Siemens PLM Software Now Sold Worldwide Through NEi Software's Reseller Network
- Engineering Simulation Software from ANSYS Used to Help Calibrate Meteorological Instruments on Phoenix Mars Lander
- Sescoi's WorkNC 5-Axis and Auto 5 - a competitive advantage at ALLIO
- Applied Technology Group named Autodesk's Reseller of the Quarter for Excellence in Customer Service
- Autodesk Acquires T-Splines Modeling Technology Assets
- Automotive Tier-One Suppliers Adopt TPM for Faster, Automated Data Translations
- New powerful functionalities for think3’s ThinkDesign 2009.1
- Michael Schley named as 2008 ifma fellow
- Visteon Technology Helps Drivers to Be More Aware of Surroundings
- PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients